An Integrated Health-System Specialty Pharmacy Model for Coordinating Transitions of Care: Specialty Medication Challenges and Specialty Pharmacist Opportunities.
access
and evaluation
comprehensive healthcare
healthcare quality
integrated delivery of healthcare
managed care
medication systems
pharmacy
programs
transitional care
Journal
Pharmacy (Basel, Switzerland)
ISSN: 2226-4787
Titre abrégé: Pharmacy (Basel)
Pays: Switzerland
ID NLM: 101678532
Informations de publication
Date de publication:
03 Dec 2019
03 Dec 2019
Historique:
received:
31
10
2019
revised:
15
11
2019
accepted:
28
11
2019
entrez:
11
12
2019
pubmed:
11
12
2019
medline:
11
12
2019
Statut:
epublish
Résumé
Adherence and persistence to specialty medications are necessary to achieve successful outcomes of costly therapies. The increasing use of specialty medications has exposed several unique barriers to certain specialty treatments' continuation. Integrated specialty pharmacy teams facilitate transitions in sites of care, between different provider types, among prescribed specialty medications, and during financial coverage changes. We review obstacles encountered within these types of transitions and the role of the specialty pharmacist in overcoming these obstacles. Case examples for each type of specialty transition provide insight into the unique complexities faced by patients, and shed light on pharmacists' vital role in patient care. This insightful and real-world experience is needed to facilitate best practices in specialty care, particularly in the growing number of health-system specialty pharmacies.
Identifiants
pubmed: 31816884
pii: pharmacy7040163
doi: 10.3390/pharmacy7040163
pmc: PMC6958321
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Res Social Adm Pharm. 2019 Jun;15(6):724-729
pubmed: 30241878
Res Social Adm Pharm. 2018 Oct;14(10):901-908
pubmed: 29050932
Am J Health Syst Pharm. 2015 May 1;72(9):695
pubmed: 25873616
Med Care. 2005 Nov;43(11):1123-9
pubmed: 16224306
Am J Health Syst Pharm. 2016 Jun 1;73(11):797-809
pubmed: 27126835
JAMA. 2018 Jun 5;319(21):2169-2170
pubmed: 29801023
J Manag Care Spec Pharm. 2016 Oct;22(10):1167-71
pubmed: 27668565
N C Med J. 2017 May-Jun;78(3):177-180
pubmed: 28576955
Health Aff (Millwood). 2001 Nov-Dec;20(6):146-60
pubmed: 11816653
Ann Intern Med. 2012 Dec 4;157(11):785-95
pubmed: 22964778
J Pediatr. 2017 Dec;191:184-189.e1
pubmed: 29037795
BMJ. 2003 Oct 11;327(7419):863-4
pubmed: 14551109
PLoS One. 2018 Jun 18;13(6):e0199174
pubmed: 29912944
J Pharm Pract. 2020 Oct;33(5):605-611
pubmed: 30700202
Am J Health Syst Pharm. 2016 Jun 1;73(11):839-43
pubmed: 27126830
J Am Pharm Assoc (2003). 2019 Jan - Feb;59(1):43-50.e3
pubmed: 30416069
J Gen Intern Med. 2019 Jan;34(1):102-109
pubmed: 30338471
J Natl Compr Canc Netw. 2009 Oct;7(9):908-42
pubmed: 19878637
Am J Health Syst Pharm. 2018 May 15;75(10):633-641
pubmed: 29610290
PLoS One. 2019 Jun 6;14(6):e0217798
pubmed: 31170217
CMAJ. 2005 Mar 29;172(7):871-2
pubmed: 15795404
J Manag Care Pharm. 2013 Sep;19(7):542-8
pubmed: 23964615
J Am Pharm Assoc (2003). 2020 Jan - Feb;60(1):163-177.e2
pubmed: 31375332
JAMA. 2019 May 28;321(20):2025-2027
pubmed: 31135837
J Med Internet Res. 2018 Oct 30;20(10):e11168
pubmed: 30377144
J Manag Care Spec Pharm. 2017 Aug;23(8):815-820
pubmed: 28737983
Am J Health Syst Pharm. 2014 Mar 15;71(6):463-9
pubmed: 24589537
Benefits Q. 2017;33(2):20-25
pubmed: 29782735
Gastroenterology. 2016 Dec;151(6):1131-1140.e5
pubmed: 27565882
J Clin Lipidol. 2019 Mar - Apr;13(2):254-264
pubmed: 30745204
Am J Health Syst Pharm. 2015 May 1;72(9):753-6
pubmed: 25873623
Ann Med. 2018 Jun;50(4):354-360
pubmed: 29629575
Am J Health Syst Pharm. 2009 Dec 15;66(24 Suppl 7):S13-20
pubmed: 19966075
Health Aff (Millwood). 2014 Oct;33(10):1714-20
pubmed: 25288414
J Am Pharm Assoc (2003). 2020 Jan - Feb;60(1):153-162.e5
pubmed: 31427210
J Oncol Pract. 2017 Jan;13(1):e29-e36
pubmed: 27922797
J Pharm Sci. 2018 Jun;107(6):1724-1730
pubmed: 29476763